New trial aims to tailor breast cancer therapy using genetic tests

NCT ID NCT05837455

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing whether using specific genetic tests (Ki67 and Oncotype DX) can help doctors choose the best treatment before surgery for women with a common type of breast cancer (ER-positive, HER2-negative). The study includes 81 postmenopausal women with stage II or III disease and focuses on improving outcomes for Black patients. The goal is to see if this personalized approach can increase tumor shrinkage and identify women who may not need chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Ki67 assay and Oncotype DX test (diagnostic devices to guide treatment choice)

What this could lead to

If successful, this approach could help personalize breast cancer treatment, potentially sparing some women from chemotherapy and improving response rates, especially for Black patients.

What could go wrong

This is a small, early-phase trial (81 participants) testing a strategy, not a new drug. The biomarker approach may not improve outcomes as hoped, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact